Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q2 2020
Top Holdings45 positions
IMMUNOMEDICS INC | 26.3M | $930.3M | 18.4% | — | — | 6 qtrssince 2019-Q1 | Increased 67 |
MIRATI THERAPEUTICS INC | 4.3M | $489.4M | 9.7% | — | — | 6 qtrssince 2019-Q1 | Increased 64 |
HORIZON THERAPEUTICS PUB L | 6M | $333.5M | 6.6% | — | — | 5 qtrssince 2019-Q2 | Increased 77 |
IOVANCE BIOTHERAPEUTICS INC | 10.4M | $284.4M | 5.6% | $12.44 | +118.65% | 6 qtrssince 2019-Q1 | Increased 70 |
SAREPTA THERAPEUTICS INC | 1.7M | $268.6M | 5.3% | $118.96 | +36.78% | 6 qtrssince 2019-Q1 | Increased 64 |
ASCENDIS PHARMA A/S | 1.8M | $258.8M | 5.1% | $117.47 | +23.61% | 6 qtrssince 2019-Q1 | Decreased 0 |
BIOMARIN PHARMACEUTICAL INC | 1.9M | $228.2M | 4.5% | $84.82 | +44.05% | 6 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE | 970,000 | $218.5M | 4.3% | $132.04 | +70.58% | 6 qtrssince 2019-Q1 | Increased 59 |
MYOKARDIA INC | 1.9M | $181.6M | 3.6% | — | — | 6 qtrssince 2019-Q1 | Increased 72 |
AMICUS THERAPEUTICS INC | 11M | $165.9M | 3.3% | $12.98 | +19.70% | 6 qtrssince 2019-Q1 | Increased 57 |
ADVERUM BIOTECHNOLOGIES INC | 7.6M | $158.4M | 3.1% | — | — | — | Increased 60 |
MERSANA THERAPEUTICS INC | 6.5M | $152.1M | 3.0% | $557.00 | 0.00% | 1 qtr | New 85 |
KARYOPHARM THERAPEUTICS INC | 7M | $132.6M | 2.6% | — | — | — | Unchanged 0 |
CONSTELLATION PHARMCETICLS I | 4M | $120.2M | 2.4% | — | — | 3 qtrssince 2019-Q4 | Increased 58 |
DECIPHERA PHARMACEUTICALS IN | 1.9M | $111.1M | 2.2% | — | — | 3 qtrssince 2019-Q4 | Decreased 0 |
ADAPTIMMUNE THERAPEUTICS PLC | 10M | $100.1M | 2.0% | $9.29 | 0.00% | 1 qtr | New 69 |
ACCELERON PHARMA INC | 1M | $99.1M | 2.0% | — | — | 2 qtrssince 2020-Q1 | Increased 57 |
UNIQURE NV | 1.5M | $67.6M | 1.3% | $64.73 | -30.38% | 4 qtrssince 2019-Q3 | Decreased 0 |
RELMADA THERAPEUTICS INC | 1.4M | $63.8M | 1.3% | $33.94 | +26.89% | 2 qtrssince 2020-Q1 | Increased 58 |
ZOGENIX INC | 2.3M | $60.8M | 1.2% | — | — | 6 qtrssince 2019-Q1 | Decreased 0 |
Avoro Capital Advisors LLC manages $5.1B across 45 positions as of Q2 2020. Top holdings: IMMU (18.4%), MRTX (9.7%), HZNP (6.6%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.
Active quarter - 8 new positions, 5 exits, 18 increased. Top move: MRSN (NEW, conviction 85). Portfolio: $5.1B across 45 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR